NeuroStar is the Only TMS System with Proven Durability Measured Over 12 Months

• Neuronetics, Data on file, NCT 00104611

• <number>

• 36.2% of patients received NeuroStar TMS reintroduction (avg. of 16 treatments)
• Physician directed standard of care
• Long term durability of effect has not been established in a randomized controlled trial

• CGI-S Outcomes Post Acute Phase

• LOCF Analysis of intent-to-treat population

• % of Patients (N=257)

• 68% of study population in response, 45% in remission